Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients with Clean Surgical Wounds.

Inclusion Criteria:

• Willing to undergo the written informed consent process prior to enrollment in thisstudy.

• At least 22 years of age at screening.

• Has non-melanoma skin cancer and be scheduled for skin cancer surgery with Mohsmicrographic surgery on a location suitable for secondary intention healing.

• Resulting surgical wound after Mohs micrographic surgery must be at least 1 cm andno more than 4 cm in diameter (or surface area of at least 0.8 cm2 and no more than 12.6 cm2).

• Resulting surgical wound after Mohs micrographic surgery must be full thickness.

• Willing to return for all required follow-up visits.

• Willing to follow the instructions of the Principal Investigator.

Exclusion Criteria:

_ Has a confirmed diagnosis of clinically significant peripheral neuropathy.

• Has uncontrolled Type I or Type II diabetes and HbA1c values greater than 8.0%within the last 6 months.

• Has a known infection in the area of the Mohs micrographic surgery.

• Has a known allergy to any of the components of the TT101 Device.

• Is an active daily cigarette smoker.

• Is pregnant or lactating.

• Is a woman of child-bearing potential who is unwilling to avoid pregnancy or use anappropriate form of birth control (adequate birth control methods are defined as:topical, oral, implantable, or injectable contraceptives; spermicide in conjunctionwith a barrier such as a condom or diaphragm; IUD; or surgical sterilization ofpartner).

• Has clinical evidence of Peripheral Vascular Disease (PVD) in the form of grade 2pitting Edema or higher.

• Has been diagnosed with a surgical or wound site infection within the last 6-months.

• Has been diagnosed with chronic ulcer or wound within the last 12- months.

• Has a remote active infection concurrent with having the Mohs micrographic surgery.

• Per Investigator's discretion the subject is not appropriate for inclusion in thetrial.